Physician profile
Jose Rivera
NPI 1003937194
$8,941.55
in general payments reported to CMS, 2019-2025
42 companies · $1,792 in 2025
The $1,792 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,048 · 2022: $2,170 · 2023: $1,537 · 2024: $1,394 · 2025: $1,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,550 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,549.75 |
| Education | $172.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $876.82 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $865.78 | 2021-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $814.00 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $705.54 | 2021-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $622.76 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $423.41 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $368.86 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $356.07 | 2021-2023 | |
| Pfizer INC. | $332.85 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $314.16 | 2021-2024 | Verquvo, Gardasil 9, Vaxelis |
| Bayer Healthcare Pharmaceuticals INC. | $313.68 | 2021-2025 | |
| Astellas Pharma US INC | $303.50 | 2021-2025 | Veozah, Myrbetriq |
| Amgen INC. | $303.28 | 2023-2025 | Krystexxa, Repatha, Otezla |
| Sumitomo Pharma America, INC. | $298.37 | 2024-2025 | Gemtesa |
| Dexcom, INC. | $250.42 | 2022-2025 | Dexcom G6 Transmitter |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $230.60 | 2022 | |
| Lundbeck LLC | $165.17 | 2023-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $137.00 | 2021-2025 | Eliquis |
| Mannkind Corporation | $130.68 | 2021-2025 | Afrezza |
| Abbvie INC. | $127.57 | 2021-2023 | |
| Eisai INC. | $125.41 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $116.02 | 2023-2025 | Rexulti |
| Amarin Pharma, INC. | $94.67 | 2021 | |
| Medtronic, INC. | $78.13 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.12 | 2022 | |
| Xeris Pharmaceuticals, INC. | $59.66 | 2021-2025 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $51.29 | 2021-2022 | |
| Hologic Sales and Service, LLC | $48.87 | 2023 | Aptima |
| Phathom Pharmaceuticals, INC. | $47.36 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $41.94 | 2021 | |
| Abbott Laboratories | $41.76 | 2022 | |
| Averitas Pharma INC. | $31.58 | 2024 | Qutenza |
| Smith+Nephew, INC. | $28.13 | 2024-2025 | Collagenase Santyl, Regranex |
| Ultragenyx Pharmaceutical INC. | $23.85 | 2021 | |
| Corcept Therapeutics | $23.33 | 2025 | Korlym |
| Lifescan, INC. | $20.71 | 2022 | |
| Exact Sciences Corporation | $19.41 | 2025 | Cologuard Collection Kit |
| Theracosbio, LLC | $18.18 | 2024 | Brenzavvy |
| Seqirus USA INC | $17.02 | 2025 | Flucelvax, Fluad |
| Horizon Therapeutics Plc | $16.54 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.03 | 2025 | Trintellix |
| Phadia US INC. | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.